A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1998-2005

  Rudman, Sarah M ^a,b   Jameson, Michael B ^f   McKeage, Mark J ^g   Savage, Philip ^c   Jodrell, Duncan I ^e   Harries, Mark ^b   Acton, Gary ^d   Erlandsson, Fredrik ^d   Spicer, James F ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d Antisoma Research Ltd   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f WAIKATO HOSPITAL   (New Zealand)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; AS 1409; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CREATININE; DACARBAZINE; FIBRONECTIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GUANOSINE TRIPHOSPHATE; HUMANIZED ANTIBODY BC1; HYBRID PROTEIN; INTERLEUKIN 12; POTASSIUM; PROTEIN ED B; SODIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANOREXIA; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CANCER CONTROL; CANCER INHIBITION; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; COOMBS POSITIVE HEMOLYTIC ANEMIA; DEHYDRATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VASCULARIZATION; UNCONSCIOUSNESS; UPPER ABDOMINAL PAIN; URINARY FREQUENCY; XEROSTOMIA;

ADULT; AGED; ANTIBODIES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 79953318400     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2490     Document Type: Article

References (15)

1. Midulla M, Verma R, Pignatelli R, Ritter MA, Courtney-Luck NS, George AJT. Source of oncofetal ED-B containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res 2000;60:164-9. (Pubitemid 30058747)
2. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337-42.
3. Villa C, Motta C, Calcagno G, Mariniari G, Lusku A, Pau A. A pilot pharmacokinetic and immunoscintigraphic study with technetium-99m-labelled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer 1997a;80:2484-9. (Pubitemid 28009502)
4. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, et al. The role of Mig, the monokine induced by interferon-gamma and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997;90:4099-105. (Pubitemid 27484065)
5. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30. (Pubitemid 23277355)
6. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-706. (Pubitemid 24251114)
7. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Can Res 1997;3:409-17. (Pubitemid 27158065)
8. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92. (Pubitemid 30305060)
9. Chiodoni C, Stoppacciaro A, Sangaletti S, Gri G, Cappetti B, Koezuka Y, et al. Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumour activity in the treatment of C-26 colon carcinoma hepatic metastases. Eur J Immuno 2001;31:3101-10. (Pubitemid 32994562)
10. Mariniari G, Lasku A, Balza E, Gaggero B, Motta C, Di Luca L, et al. Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer 1997b;87:2378-84. (Pubitemid 28009489)
11. Lo K-M, Lan Y, Lauder S, Zhang J, Brunkhorst B, Qin G, et al. huBC-IL12, an immunocytokine which targets EDB containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother 2007;56:447-57. (Pubitemid 46204531)
12. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin- 12 associated toxicity and interferon-gamma production. Blood 1997;90:2541-8. (Pubitemid 27413462)
13. Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamidotriazole (CAI), TNP-470 and interleukin-12. Angiogenesis 1997;1:23-5.
14. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004;22:4463-73. (Pubitemid 41185112)
15. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B containing fibronectin isoform in haemtologic tumours enables ED-B targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009;113:2265-74.